Original Paper

Survival rate of patients with esophageal squamous cell carcinoma

Basi A (M.D)\textsuperscript{1}, Nikofar AR (M.D)\textsuperscript{2}, Azhdarkosh H (M.D)\textsuperscript{3}, Ordoni Aval P (M.D)*\textsuperscript{4}, Ordoni Aval Z (M.Sc)\textsuperscript{5}

\textsuperscript{1}Associate Professor, Hematologist and Oncologist, Iran University of Medical Sciences, Tehran, Iran. \textsuperscript{2}Assistant Professor, Radiotherapist, Iran University of Medical Sciences, Tehran, Iran. \textsuperscript{3}Assistant Professor, Gastroenterologist, Iran University of Medical Sciences, Tehran, Iran. \textsuperscript{4}Resident in Internal Medicine, Iran University of Medical Sciences, Tehran, Iran. \textsuperscript{5}Midwifery, Golestan University of Medical Sciences, Gorgan, Iran.

Abstract

\textbf{Background and Objective:} Squamous carcinoma accounts for the majority of esophageal carcinoma worldwide. This study was done to evaluate the survival rate of patients with esophageal cancer in Iran.

\textbf{Methods:} This historical cohort study was carried out on 105 patients with esophageal squamous cell carcinoma whom admitted to Firoozgar hospital in Tehran, Iran during 2009-14. Patients with esophageal squamous cell carcinoma were treated with chemoradiation either with or without surgery.

\textbf{Results:} The mean age of patients was 63 years. Frequency of esophageal cancer in both sexes in the age group 51-60 years was higher than other groups. 5-year survival in patients with esophageal cancer treated with chemoradiation without surgery was 9.5\% and in patients treated with chemoradiation with surgery was 31.7\% (P<0.05). One-year, three-year and five-year survival rate in patients were treated with chemoradiation with or without surgery was 68.5\%, 38\% and 22.8\%, respectively.

\textbf{Conclusion:} The survival rate of patients with esophageal cancer is very low, but the treatment with chemoradiation with surgery can increase life expectancy of patients.

\textbf{Keywords:} Esophagus, Squamous cell carcinoma, Survival, Chemotherapy, Chemoradiation, Surgery

* \textbf{Corresponding Author:} Ordoni Aval H (M.D), E-mail: parviz_ordoni@yahoo.com

\textbf{Received} 7 May 2016 \hspace{1cm} \textbf{Revised} 16 Aug 2016 \hspace{1cm} \textbf{Accepted} 29 Aug 2016